Chemotherapy‐induced alopecia: an exploratory questionnaire‐based study from Israel comparing knowledge, attitudes, and management practices among dermatologists and oncologists

BACKGROUND AND OBJECTIVES: Chemotherapy-induced alopecia, encompassing both acute reversible alopecia and its persistent form, significantly impacts patients' quality of life but remains inadequately addressed. This study aimed to compare dermatologists' and oncologists' knowledge, attitudes, and practices regarding chemotherapy-induced alopecia, as well as their awareness of scalp cooling as a preventive intervention. PATIENTS AND METHODS: A cross-sectional survey was conducted in Israel at nine tertiary medical centers using a structured questionnaire to assess knowledge, attitudes, and practices related to chemotherapy-induced alopecia, including separately analyzed persistent chemotherapy-induced alopecia and scalp cooling. Responses from dermatologists and oncologists were compared, and factors influencing knowledge scores were identified. RESULTS: Both groups demonstrated limited knowledge. Oncologists scored higher on acute chemotherapy-induced alopecia (mean 3.88 vs. 2.74, p < 0.001), while dermatologists tended to score higher on persistent chemotherapy-induced alopecia (mean 7.85 vs. 6.92, p = 0.063). Male participants scored lower than female participants (p = 0.050). Oncologists were more familiar with scalp cooling, citing cost and logistical issues as significant barriers; dermatologists emphasized the need for proactive care and education. CONCLUSIONS: Significant knowledge gaps and differing practices between dermatologists and oncologists underscore the importance of targeted educational initiatives and interdisciplinary collaboration to improve patient care.